Finance

Lister
1ZTS:BIT
Zoetis Inc
61,60 €
−0,93%
(−0,58) 1 D
2. okt., 17:26:00 GMT+2  ·   EUR
Alle symboler
SymbolPrisEndringEndring (%)
Genererer viktig statistikk for 1ZTS …
Åpne
61,60 €
Høy
61,60 €
Lav
61,60 €
Markedsverdi
30,91 mrd.
Snittvolum
384,00
Volum
8,00
52 u høy
130,06 €
52 u lav
61,04 €
Antall ansatte
14k
Åpne
61,60 €
Høy
61,60 €
Lav
61,60 €
Markedsverdi
30,91 mrd.
Snittvolum
384,00
Volum
8,00
52 u høy
130,06 €
52 u lav
61,04 €
Antall ansatte
14k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Profil
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
Om Zoetis Inc
Administrerende direktørKristin C. Peck
Ansatte14,5k
Grunnlagt1952
HovedkontorParsippany-Troy Hills, New Jersey, USA
Sektor-
Nettstedzoetis.com
Tidligere rapporterAlle verdier i USD
Loading Previous Earnings...
Inntekt
Nettoinntekt
Alle verdier i USD
sep. 2025
des. 2025
mars 2026
juni 2026
Inntekt
2,40 mrd.
2,39 mrd.
2,26 mrd.
2,47 mrd.
Varekostnad
682,00 mill.
711,00 mill.
640,00 mill.
670,00 mill.
Direkte driftskostnader
682,00 mill.
711,00 mill.
640,00 mill.
670,00 mill.
Utgifter til forskning og utvikling
170,00 mill.
199,00 mill.
180,00 mill.
173,00 mill.
Totale kostnader til forskning og utvikling
-
-
-
-
Salgskostnader, generelle kostnader og administrative kostnader
572,00 mill.
618,00 mill.
584,00 mill.
589,00 mill.
Driftskostnader
774,00 mill.
848,00 mill.
795,00 mill.
793,00 mill.
Totale driftskostnader
1,46 mrd.
1,56 mrd.
1,44 mrd.
1,46 mrd.
Driftsinntekter
944,00 mill.
828,00 mill.
827,00 mill.
1,00 mrd.
Andre ikke-operasjonelle inntekter
-
−6,00 mill.
−1,00 mill.
−2,00 mill.
EBT inkludert uvanlige elementer
887,00 mill.
761,00 mill.
758,00 mill.
866,00 mill.
EBT uten uvanlige elementer
899,00 mill.
780,00 mill.
779,00 mill.
948,00 mill.
Kostnad for inntektsskatt
166,00 mill.
158,00 mill.
157,00 mill.
175,00 mill.
Faktisk avgiftssats
18,71 %
20,76 %
20,71 %
20,21 %
Andre driftskostnader
-
-
-
-
Nettoinntekt
721,00 mill.
603,00 mill.
601,00 mill.
691,00 mill.
Netto fortjenestemargin
30,04 %
25,26 %
26,57 %
28,00 %
Resultat per aksje
1,70
1,48
1,53
1,87
Rente- og investeringsinntekter
26,00 mill.
25,00 mill.
21,00 mill.
16,00 mill.
Rentekostnader
−58,00 mill.
−57,00 mill.
−62,00 mill.
−61,00 mill.
Netto rentekostnader
−32,00 mill.
−32,00 mill.
−41,00 mill.
−45,00 mill.
Avskrivnings- og amortiseringskostnader
-
-
-
-
EBITDA
1,07 mrd.
903,00 mill.
946,00 mill.
1,12 mrd.
Gevinst eller tap ved salg av eiendeler
-
-
−6,00 mill.
−1,00 mill.
AI-innhold kan inneholde feil. Finn ut mer
Google-apper